Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Xbiotech Inc (XBIT)

Xbiotech Inc (XBIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 240,867
  • Shares Outstanding, K 30,451
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,560 K
  • 60-Month Beta 1.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.25
Trade XBIT with:

Options Overview Details

View History
  • Implied Volatility 157.31% ( +82.37%)
  • Historical Volatility 98.39%
  • IV Percentile 68%
  • IV Rank 53.82%
  • IV High 288.38% on 02/02/24
  • IV Low 4.53% on 08/10/23
  • Put/Call Vol Ratio 0.91
  • Today's Volume 42
  • Volume Avg (30-Day) 17
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 265
  • Open Int (30-Day) 186

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.78 +18.58%
on 03/20/24
9.96 -19.28%
on 04/10/24
+0.93 (+13.08%)
since 03/19/24
3-Month
4.14 +93.97%
on 01/26/24
9.96 -19.28%
on 04/10/24
+3.39 (+72.90%)
since 01/19/24
52-Week
3.05 +163.61%
on 04/27/23
9.96 -19.28%
on 04/10/24
+4.54 (+129.71%)
since 04/19/23

Most Recent Stories

More News
XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study

Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic Cancer...

XBIT : 8.04 (+1.64%)
Oversold Conditions For XBiotech (XBIT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

XBIT : 8.04 (+1.64%)
XBiotech Inks Clinical Manufacturing Deal

XBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson & Johnson...

XBIT : 8.04 (+1.64%)
XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic Disease...

XBIT : 8.04 (+1.64%)
XBiotech to Launch Novel Candidate Therapy for Stroke

Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke...

XBIT : 8.04 (+1.64%)
Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced that Benjamin Musher M.D., will chair XBiotech’s clinical program for pancreatic cancer....

XBIT : 8.04 (+1.64%)
XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director

Dr. Ziats Joins Clinical Team Involved in Launch and Management of Clinical Studies Across Multiple Indications

XBIT : 8.04 (+1.64%)
XBiotech Announces Payment of Dividend to Holders of Common Stock

Company distributed USD $75 Million to Shareholders

XBIT : 8.04 (+1.64%)
XBiotech Announces Dividend to Holders of Common Stock

AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.’s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or...

XBIT : 8.04 (+1.64%)
XBiotech Announces Receipt of $75 Million from Sale of Antibody

Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody

XBIT : 8.04 (+1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

XBiotech Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing True Human(TM) monoclonal antibodies for treating diseases. XBiotech Inc. is based in AUSTIN, United States.

See More

Key Turning Points

3rd Resistance Point 9.26
2nd Resistance Point 8.80
1st Resistance Point 8.42
Last Price 8.04
1st Support Level 7.58
2nd Support Level 7.12
3rd Support Level 6.74

See More

52-Week High 9.96
Last Price 8.04
Fibonacci 61.8% 7.32
Fibonacci 50% 6.51
Fibonacci 38.2% 5.69
52-Week Low 3.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar